{
    "0P00000E7S.F": {
        "short_name": "Ibercaja Sanidad A FI",
        "long_name": "Ibercaja Sanidad A FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia la rentabilidad del \u00c3\u00adndice 60 % * MSCI World Health Care USD + 35% * MSCI Europe Health Care Index + 5% Simult\u00c3\u00a1nea mes Zona Euro Exposici\u00c3\u00b3n, directa o indirectamente (m\u00c3\u00a1ximo 10% a trav\u00c3\u00a9s de IIC), de al menos un 75% en renta variable de empresas dedicadas al cuidado de la salud, incluido equipamiento sanitario, aprovisionamientos sanitarios, distribuidores de productos, proveedores de servicios, gestores y due\u00c3\u00b1os de instalaciones como hospitales, centros de la 3\u00c2\u00aa edad, etc, proveedores de tecnolog\u00c3\u00ada, compa\u00c3\u00b1\u00c3\u00adas biotecnol\u00c3\u00b3gicas, compa\u00c3\u00b1\u00c3\u00adas farmace\u00c3\u00baticas y las relacionadas con otras actividades de investigaci\u00c3\u00b3n, desarrollo y producci\u00c3\u00b3n de f\u00c3\u00a1rmacos.",
        "manager_name": "Miriam  Fern\u00c3\u00a1ndez Jim\u00c3\u00a9nez",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Ibercaja Gesti\u00c3\u00b3n SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00000P3N.F": {
        "short_name": "NB Pharmafund FI",
        "long_name": "NB Pharmafund FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia el comportamiento del \u00c3\u00adndice MSCI New Global Industries World Health. El fondo tendr\u00c3\u00a1 m\u00c3\u00a1s del 75% de la exposici\u00c3\u00b3n total a renta variable, nacional e internacional, de compa\u00c3\u00b1\u00c3\u00adas relacionadas con el sector de la salud (empresas farmac\u00c3\u00a9uticas, de instrumentos m\u00c3\u00a9dicos, de biotecnolog\u00c3\u00ada, de perfumer\u00c3\u00ada, de cosm\u00c3\u00a9tica, de seguros sanitarios, etc).El resto de la exposici\u00c3\u00b3n se alcanzar\u00c3\u00a1 en renta fija p\u00c3\u00bablica y/o privada (incluidos dep\u00c3\u00b3sitos e instrumentos del mercado monetario cotizados o no cotizados que sean l\u00c3\u00adquidos), sin ninguna limitaci\u00c3\u00b3n por calidad crediticia o duraci\u00c3\u00b3n, pudiendo estar invertido hasta el 25% en activos de baja calidad crediticia (inferior a BBB- seg\u00c3\u00ban S&P).",
        "manager_name": "Jos\u00c3\u00a9 Ram\u00c3\u00b3n  Boluda",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Novo Banco Gesti\u00c3\u00b3n SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00000PK1.F": {
        "short_name": "Caixabank Multisalud Estandar ",
        "long_name": "Caixabank Multisalud Estandar FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia la rentabilidad del \u00c3\u00adndice MSCI World Health Care. Entre el 75% y el 100% de la exposici\u00c3\u00b3n ser\u00c3\u00a1 en valores de renta variable, cotizados en mercados autorizados, de compa\u00c3\u00b1\u00c3\u00adas del sector de la salud. Estas inversiones se materializan en valores de baja, media y/o, fundamentalmente, alta capitalizaci\u00c3\u00b3n burs\u00c3\u00a1til y se dirigen principalmente al mercado americano y europeo complementado con algunas de las compa\u00c3\u00b1\u00c3\u00adas japonesas m\u00c3\u00a1s importantes. La inversi\u00c3\u00b3n m\u00c3\u00a1xima en activos de pa\u00c3\u00adses emergentes ser\u00c3\u00a1 del 15%. La exposici\u00c3\u00b3n a riesgo divisa podr\u00c3\u00a1 superar el 30%.",
        "manager_name": "Jordi  Mas",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Caixabank Asset Management SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00000PPN.F": {
        "short_name": "Arc Actions Sant\u00e9 InnovanteA",
        "long_name": "Arc Actions Sant&#195;&#169; InnovanteA",
        "currency": "EUR",
        "summary": "L\u00e2\u0080\u0099objectif de gestion du Fonds vise \u00c3\u00a0 obtenir sur la p\u00c3\u00a9riode d\u00e2\u0080\u0099investissement recommand\u00c3\u00a9e, une performance nette de frais de gestion sup\u00c3\u00a9rieure \u00c3\u00a0 celle de l\u00e2\u0080\u0099indice MSCI World Health Care Net Daily Total Return converti en euro pour la part A et en dollar pour la part B. Les dividendes sont r\u00c3\u00a9investis selon la m\u00c3\u00a9thodologie de MSCI (cf. cidessous).",
        "manager_name": "Xavier  d'Ornellas",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Financi\u00c3\u00a8re de l&#39;Arc",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00000QBA.F": {
        "short_name": "BSO Bio Sant\u00e9 C",
        "long_name": "BSO Bio Sant&#195;&#169; C",
        "currency": "EUR",
        "summary": "L\u00e2\u0080\u0099objectif de gestion est la recherche d\u00e2\u0080\u0099une performance sup\u00c3\u00a9rieure, sur la dur\u00c3\u00a9e de placement recommand\u00c3\u00a9e de cinq ans, \u00c3\u00a0 cel le de l\u00e2\u0080\u0099indicateur de r\u00c3\u00a9f\u00c3\u00a9rence, \u00c3\u00a0 savoir l\u00e2\u0080\u0099indice MSCI World Health Care en euro, calcul\u00c3\u00a9 dividendes net r\u00c3\u00a9investis.\nL\u00e2\u0080\u0099indicateur sert de r\u00c3\u00a9f\u00c3\u00a9rence \u00c3\u00a0 posteriori : la gestion de l\u00e2\u0080\u0099OPCVM n&#39;\u00c3\u00a9tant pas indicielle, sa performance pourra, le cas \u00c3\u00a9ch\u00c3\u00a9ant, s&#39;en \u00c3\u00a9carter sensiblement.",
        "manager_name": "R\u00c3\u00a9my  Plantevin",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Saint Olive Gestion",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00006HYY.SI": {
        "short_name": "United Global Healthcare Fund -",
        "long_name": "UOB United Global Healthcare Fund SGD Acc",
        "currency": "SGD",
        "summary": "The investment objective of the Fund is to achieve long term capital growth by investing in securities issued by companies principally involved in the development, production or distribution of products, equipment and/or services related to healthcare, in any part of the world. Such investments would include investing in sub-sectors of the healthcare industry such as medical products, health services, major pharmaceuticals, specialty major pharmaceuticals, and specialty pharmaceuticals.",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "UOB Asset Management Ltd",
        "exchange": "SES",
        "market": "sg_market"
    },
    "0P0000HLYB.F": {
        "short_name": "Albemarle Longevity Fund Class",
        "long_name": "Albemarle Longevity Fund Class A",
        "currency": "EUR",
        "summary": "Albemarle Longevity Fund is an open-end fund incorporated in Ireland. The Fund aims to achieve long term capital appreciation by investing in stocks which could benefit the most from the long-term demographic trend of ageing population. The Fund will have a predominant exposure to Europe.",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Albemarle Asset Management Ltd",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P0000U1SX.F": {
        "short_name": "Albemarle Longevity Fund Class",
        "long_name": "Albemarle Longevity Fund Class I",
        "currency": "EUR",
        "summary": "Albemarle Longevity Fund is an open-end fund incorporated in Ireland. The Fund aims to achieve long term capital appreciation by investing in stocks which could benefit the most from the long-term demographic trend of ageing population. The Fund will have a predominant exposure to Europe.",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Albemarle Asset Management Ltd",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P0000U2IC.F": {
        "short_name": "Ibercaja Sanidad B FI",
        "long_name": "Ibercaja Sanidad B FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia la rentabilidad del \u00c3\u00adndice 60 % * MSCI World Health Care USD + 35% * MSCI Europe Health Care Index + 5% Simult\u00c3\u00a1nea mes Zona Euro Exposici\u00c3\u00b3n, directa o indirectamente (m\u00c3\u00a1ximo 10% a trav\u00c3\u00a9s de IIC), de al menos un 75% en renta variable de empresas dedicadas al cuidado de la salud, incluido equipamiento sanitario, aprovisionamientos sanitarios, distribuidores de productos, proveedores de servicios, gestores y due\u00c3\u00b1os de instalaciones como hospitales, centros de la 3\u00c2\u00aa edad, etc, proveedores de tecnolog\u00c3\u00ada, compa\u00c3\u00b1\u00c3\u00adas biotecnol\u00c3\u00b3gicas, compa\u00c3\u00b1\u00c3\u00adas farmace\u00c3\u00baticas y las relacionadas con otras actividades de investigaci\u00c3\u00b3n, desarrollo y producci\u00c3\u00b3n de f\u00c3\u00a1rmacos.",
        "manager_name": "Miriam  Fern\u00c3\u00a1ndez Jim\u00c3\u00a9nez",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Ibercaja Gesti\u00c3\u00b3n SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P0000XMSV.L": {
        "short_name": "AXA Framlington Health Fund Z G",
        "long_name": "AXA Framlington Health Fund Z GBP Acc",
        "currency": "GBp",
        "summary": "The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon analysis of a company\u00e2\u0080\u0099s financial status, quality of its management, expected profitability and prospects for growth.",
        "manager_name": "Dani  Saurymper",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "AXA Investment Managers UK Ltd",
        "exchange": "LSE",
        "market": "gb_market"
    },
    "0P0000XTT7.F": {
        "short_name": "Trecento Sant\u00e9 ISR R EUR",
        "long_name": "Trecento Sant&#195;&#169; ISR R EUR",
        "currency": "EUR",
        "summary": "Trecento Sant\u00c3\u00a9 ISR est un fonds qui investit en actions de soci\u00c3\u00a9t\u00c3\u00a9s internationales issues du secteur de la sant\u00c3\u00a9 (notamment les laboratoires pharmaceutiques, les biotechnologies, le mat\u00c3\u00a9riel m\u00c3\u00a9dical, les services de sant\u00c3\u00a9) et ce sans r\u00c3\u00a9f\u00c3\u00a9rence \u00c3\u00a0 un indice. Le fonds Trecento Sant\u00c3\u00a9 ISR a pour objectif d\u00e2\u0080\u0099offrir une performance annuelle sup\u00c3\u00a9rieure \u00c3\u00a0 7% nette de frais pour les parts \u00c2\u00ab R EUR \u00c2\u00bb, \u00c2\u00ab R CHF \u00c2\u00bb et \u00c2\u00ab R USD \u00c2\u00bb et sup\u00c3\u00a9rieure \u00c3\u00a0 8% nette de frais pour la part \u00c2\u00ab I EUR \u00c2\u00bb. Cet objectif de performance est associ\u00c3\u00a9 \u00c3\u00a0 un objectif de gestion extra-financier visant \u00c3\u00a0 exclure les soci\u00c3\u00a9t\u00c3\u00a9s aux pratiques ESG (Environnement, Social, Gouvernance) contestables (via une politique d\u00e2\u0080\u0099exclusion normative et sectorielle) et \u00c3\u00a0 s\u00c3\u00a9lectionner les soci\u00c3\u00a9t\u00c3\u00a9s affichant les meilleures pratiques ESG \u00e2\u0080\u0093 approche \u00c2\u00ab best-in-class \u00c2\u00bb.",
        "manager_name": "Alice  Lhabouz",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Trecento Asset Management",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P000156VT.F": {
        "short_name": "nova Steady HealthCare P",
        "long_name": "nova Steady HealthCare P",
        "currency": "EUR",
        "summary": "n/a",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Axxion S.A.",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00015JIF.F": {
        "short_name": "apo Medical Opportunities Insti",
        "long_name": "apo Medical Opportunities Institutionell",
        "currency": "EUR",
        "summary": "n/a",
        "manager_name": "Kai  Br\u00c3\u00bcning",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "INKA Internationale KAG mbH",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00016BB7.HK": {
        "short_name": "BOCIP China Health Care Fund A",
        "long_name": "BOCIP China Health Care Fund A",
        "currency": "HKD",
        "summary": "The Sub-Fund seeks to provide investors with long-term capital appreciation by investing in securities that design, make or sell products and services related to health care industry in the People\u00e2\u0080\u0099s Republic of China (\u00e2\u0080\u009cPRC\u00e2\u0080\u009d). Such theme-specific securities include companies in the PRC (i) that are engaged in pharmaceuticals, biotechnology, medical devices or technology,surgical research or equipment, healthcare provision and consultation, health or nutrition\nsupplements research or production, ownership and/or management of or provision of services relating to hospitals, nursing homes or health maintenance organizations, infancy care centres or after-life service organizations; or (ii) companies having their major business activities related or connected to healthcare sector.",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "BOCI-Prudential Asset Management Ltd",
        "exchange": "HKG",
        "market": "hk_market"
    },
    "0P00017IUO.F": {
        "short_name": "Caixabank Multisalud Premium FI",
        "long_name": "Caixabank Multisalud Premium FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia la rentabilidad del \u00c3\u00adndice MSCI World Health Care. Entre el 75% y el 100% de la exposici\u00c3\u00b3n ser\u00c3\u00a1 en valores de renta variable, cotizados en mercados autorizados, de compa\u00c3\u00b1\u00c3\u00adas del sector de la salud. Estas inversiones se materializan en valores de baja, media y/o, fundamentalmente, alta capitalizaci\u00c3\u00b3n burs\u00c3\u00a1til y se dirigen principalmente al mercado americano y europeo complementado con algunas de las compa\u00c3\u00b1\u00c3\u00adas japonesas m\u00c3\u00a1s importantes. La inversi\u00c3\u00b3n m\u00c3\u00a1xima en activos de pa\u00c3\u00adses emergentes ser\u00c3\u00a1 del 15%. La exposici\u00c3\u00b3n a riesgo divisa podr\u00c3\u00a1 superar el 30%.",
        "manager_name": "Jordi  Mas",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Caixabank Asset Management SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P00017IVH.F": {
        "short_name": "Caixabank Multisalud Plus FI",
        "long_name": "Caixabank Multisalud Plus FI",
        "currency": "EUR",
        "summary": "La gesti\u00c3\u00b3n toma como referencia la rentabilidad del \u00c3\u00adndice MSCI World Health Care. Entre el 75% y el 100% de la exposici\u00c3\u00b3n ser\u00c3\u00a1 en valores de renta variable, cotizados en mercados autorizados, de compa\u00c3\u00b1\u00c3\u00adas del sector de la salud. Estas inversiones se materializan en valores de baja, media y/o, fundamentalmente, alta capitalizaci\u00c3\u00b3n burs\u00c3\u00a1til y se dirigen principalmente al mercado americano y europeo complementado con algunas de las compa\u00c3\u00b1\u00c3\u00adas japonesas m\u00c3\u00a1s importantes. La inversi\u00c3\u00b3n m\u00c3\u00a1xima en activos de pa\u00c3\u00adses emergentes ser\u00c3\u00a1 del 15%. La exposici\u00c3\u00b3n a riesgo divisa podr\u00c3\u00a1 superar el 30%.",
        "manager_name": "Jordi  Mas",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Caixabank Asset Management SGIIC",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "0P0001J72Z.F": {
        "short_name": "Renta 4 Megatendencias Salud, I",
        "long_name": null,
        "currency": "EUR",
        "summary": "La exposici\u00c3\u00b3n a renta variable ser\u00c3\u00a1 como m\u00c3\u00adnimo del 75%, exclusivamente en empresas relacionadas con el sector de cuidados de la salud, que incluye los sub-sectores biotecnol\u00c3\u00b3gico, farmac\u00c3\u00a9utico, equipos m\u00c3\u00a9dicos, gesti\u00c3\u00b3n de la salud, cosm\u00c3\u00a9tica, as\u00c3\u00ad como en empresas de servicios, distribuci\u00c3\u00b3n, suministros, instalaciones o herramientas vinculados a dichos sectores, todo ello sin l\u00c3\u00admite en t\u00c3\u00a9rminos de distribuci\u00c3\u00b3n geogr\u00c3\u00a1fica ni capitalizaci\u00c3\u00b3n, por lo que se podr\u00c3\u00a1 invertir en compa\u00c3\u00b1\u00c3\u00adas de baja, mediana y elevada capitalizaci\u00c3\u00b3n burs\u00c3\u00a1til.",
        "manager_name": "",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Renta 4 Gestora SGIIC S.A.",
        "exchange": "FRA",
        "market": "dr_market"
    },
    "LSP.AS": {
        "short_name": "LSP LIFE SCIENCES",
        "long_name": "LSP Life Sciences Fund N.V.",
        "currency": "EUR",
        "summary": "The Fund&#39;s primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund\u00e2\u0080\u0099s portfolio will consist of European and American companies listed on one of the (main) stock exchanges, with a market capitalization of below EUR 2.5 billion at the time of investment.",
        "manager_name": "Mark  Wegter",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "Life Sciences Partners",
        "exchange": "AMS",
        "market": "nl_market"
    },
    "SELJLP.MI": {
        "short_name": "SELECTRA J. LAMARCK PHARMA CLAS",
        "long_name": "Selectra Investments Sicav - J Lamarck Pharma D",
        "currency": "EUR",
        "summary": "The main objective of this Sub-Fund is to profit from increasing share prices in the pharmaceutical sector worldwide. The focus is on mature top tier pharmaceutical companies and companies with interesting pipeline of products in development in a single or numerous markets. The followed investment policy will enable the Sub-Fund to increase overall return by active stock selection of companies, offering the most promising technology platform.",
        "manager_name": "",
        "manager_bio": "",
        "category": "Sector Equity Healthcare",
        "family": "SELECTRA MANAGEMENT COMPANY S.A.",
        "exchange": "MIL",
        "market": "it_market"
    }
}